These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 31593795)
1. Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (β-amino ester) nano-vaccines for melanoma. Zou C; Jiang G; Gao X; Zhang W; Deng H; Zhang C; Ding J; Wei R; Wang X; Xi L; Tan S Nanomedicine; 2019 Nov; 22():102092. PubMed ID: 31593795 [TBL] [Abstract][Full Text] [Related]
2. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522 [TBL] [Abstract][Full Text] [Related]
3. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy. Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883 [TBL] [Abstract][Full Text] [Related]
4. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213 [TBL] [Abstract][Full Text] [Related]
5. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847 [TBL] [Abstract][Full Text] [Related]
6. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918 [TBL] [Abstract][Full Text] [Related]
7. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma. Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699 [TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine. Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821 [TBL] [Abstract][Full Text] [Related]
9. Pickering emulsion-guided monomeric delivery of monophosphoryl lipid A for enhanced vaccination. Du Y; Lv J; Hao Z; Li Z; Song T; Ge H; Wang H; Yu Z; Xie Z; Li D; Liu Y J Control Release; 2024 Oct; 374():39-49. PubMed ID: 39111597 [TBL] [Abstract][Full Text] [Related]
10. Co-delivery of anionic epitope/CpG vaccine and IDO inhibitor by self-assembled cationic liposomes for combination melanoma immunotherapy. Su Q; Wang C; Song H; Zhang C; Liu J; Huang P; Zhang Y; Zhang J; Wang W J Mater Chem B; 2021 May; 9(18):3892-3899. PubMed ID: 33928989 [TBL] [Abstract][Full Text] [Related]
11. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma. Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897 [TBL] [Abstract][Full Text] [Related]
12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962 [TBL] [Abstract][Full Text] [Related]
13. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039 [TBL] [Abstract][Full Text] [Related]
14. Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies. Zhang W; Lim SM; Hwang J; Ramalingam S; Kim M; Jin JO Cancer Immunol Immunother; 2021 Mar; 70(3):689-700. PubMed ID: 32902663 [TBL] [Abstract][Full Text] [Related]
15. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide. Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352 [TBL] [Abstract][Full Text] [Related]
16. Nanotechnology-Based Cancer Vaccine. Alshamsan A Methods Mol Biol; 2017; 1530():257-270. PubMed ID: 28150207 [TBL] [Abstract][Full Text] [Related]
17. Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo. Luo Z; Wang C; Yi H; Li P; Pan H; Liu L; Cai L; Ma Y Biomaterials; 2015 Jan; 38():50-60. PubMed ID: 25457983 [TBL] [Abstract][Full Text] [Related]
18. Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer. Zhou Y; Wei R; Wang L; Li J; Wang W; Jiang G; Tan S; Li F; Wang X; Ma X; Xi L J Nanobiotechnology; 2024 Aug; 22(1):483. PubMed ID: 39138475 [TBL] [Abstract][Full Text] [Related]
19. In vivo targeting of DNA vaccines to dendritic cells using functionalized gold nanoparticles. Gulla SK; Rao BR; Moku G; Jinka S; Nimmu NV; Khalid S; Patra CR; Chaudhuri A Biomater Sci; 2019 Feb; 7(3):773-788. PubMed ID: 30601510 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cell activation by an E. coli-derived monophosphoryl lipid A enhances the efficacy of PD-1 blockade. Jeong Y; Kim GB; Ji Y; Kwak GJ; Nam GH; Hong Y; Kim S; An J; Kim SH; Yang Y; Chung HS; Kim IS Cancer Lett; 2020 Mar; 472():19-28. PubMed ID: 31857157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]